• Gamithromycin: Mechanism, PK/PD, and Workflows

  2026-08-25

  Gamithromycin, also known as ML-1709460, is a 15-membered semi-synthetic macrolide antibiotic for respiratory-pathogen research and veterinary applications. Its principal value is target-site exposure in lung tissue and pulmonary epithelial lining fluid, interpreted with the AUC24h/MIC pharmacodynamic index.

• Azilsartan (TAK-536): From AT1 Biology to Translation

  2026-08-24

  Azilsartan (TAK-536) provides a precise way to interrogate AT1 receptor signaling across cardiovascular, renin-angiotensin system, and neuroinflammation models. This article connects mechanistic findings from reactive astrocyte–microglia research with practical study design, product handling, and translational strategy.

• Gepotidacin Pharmacokinetics in Adults and Elderly

  2026-08-24

  This phase I reference study characterizes the pharmacokinetics, safety, and tolerability of Gepotidacin, also known as GSK2140944, across single and repeat oral dosing in healthy adults and elderly participants. Its dose-proportional exposure, predictable accumulation, and limited food effect provide a translational foundation for further antibacterial development while distinguishing pharmacokinetic evidence from clinical efficacy.

• Sisomicin vs Tobramycin: In Vitro Activity

  2026-08-23

  Stewart and Bodey evaluated sisomicin against 565 clinical isolates and compared its minimum inhibitory concentrations with gentamicin, Tobramycin, amikacin, butirosin, and kanamycin. The study showed strong activity against most Gram-negative bacilli, while its cross-resistance pattern with gentamicin and Tobramycin highlighted the importance of amikacin for antibiotic resistance research.

• Geneticin, G-418 Sulfate: Assay Reliability

  2026-08-22

  A scenario-driven guide to using Geneticin, G-418 Sulfate (SKU A2513) for cell selection, viability, proliferation, cytotoxicity, and antiviral workflows. It connects mechanism, stock preparation, kill-curve design, data interpretation, and practical product-selection criteria for more defensible laboratory results.

• CAPE Inhibits TcdB and Modulates CDI

  2026-08-22

  The reference study identifies caffeic acid phenethyl ester (CAPE) as a candidate antivirulence compound that inhibits the Clostridioides difficile toxin TcdB while reshaping infection-associated gut microbiota. Its combination of phenotypic screening, toxin-mechanism assays, mouse infection experiments, microbiome profiling, and metabolite analysis provides a useful framework for developing anti-infection research strategies that do not rely solely on bacterial killing.

• Cefoperazone: From MIC Data to Biliary Models

  2026-08-21

  Cefoperazone sodium salt connects β-lactamase-resistance research with reproducible antimicrobial assays and biliary tract infection models. This article interprets historical comparative data and translates the compound’s physicochemical and pharmacokinetic properties into practical experimental decisions.

• Temafloxacin Against Gram-Positive Bacteria

  2026-08-20

  The 1991 reference study combined new broth microdilution data with a literature review to define temafloxacin’s enhanced in-vitro activity against clinically important Gram-positive cocci. Its comparisons with ciprofloxacin and ofloxacin, together with testing under altered pH, serum, urine, magnesium, and inoculum conditions, provide a useful framework for interpreting fluoroquinolone susceptibility assays.

• Temafloxacin Combinations in Mycobacterium avium Complex

  2026-08-20

  A 1993 study evaluated clarithromycin, temafloxacin, and ethambutol against pigmented and non-pigmented Mycobacterium avium complex strains using extracellular MIC/FIC testing and macrophage-based intracellular killing assays. The results showed that combination activity was strain-dependent, while the three-drug regimen produced the strongest intracellular bactericidal effect, supporting combination screening rather than reliance on single-agent MICs alone.

• Ceftazidime in Gram-Negative Infection Research

  2026-08-19

  Ceftazidime combines strong activity against aerobic Gram-negative bacteria, including Pseudomonas aeruginosa, with a practical workflow for susceptibility, infection-model, and resistance-transmission studies. This guide translates recent carbapenem-resistant Enterobacter cloacae findings into assay design, stock handling, controls, and troubleshooting decisions.

• Penicillin G Sodium: Workflow and Assay Optimization

  2026-08-19

  Build reproducible susceptibility, time-kill, and infection-model workflows with Penicillin G Sodium while accounting for penicillinase activity, solution stability, and exposure timing. The article also adapts a mechanistic assay-design lesson from oncology research without conflating 5-azacytidine findings with antibiotic biology.

• ZCL278 and the Translational Logic of Cdc42 Inhibition

  2026-08-18

  Cdc42 is emerging as a mechanistically actionable node in cell migration, neuronal development, and kidney fibrosis. This thought-leadership guide positions ZCL278 as a research tool for connecting biochemical target engagement with spatial phenotypes and fibrosis-relevant signaling, while distinguishing validated evidence from translational hypotheses.

• Sodium Picosulfate in Gut–Liver–Brain Research

  2026-08-18

  Sodium Picosulfate offers a defined way to perturb intestinal water and electrolyte handling while tracking fecal, hepatic, and neuroinflammatory readouts. This workflow-oriented guide connects constipation-model design with regional [18F]PBR146 PET/CT findings, without overstating evidence that the compound itself was tested in the reference study.

• Shufeng Xingbi Therapy in Allergic Rhinitis Rats

  2026-08-17

  This preprint examines how Shufeng Xingbi Therapy affects allergic rhinitis in OVA-sensitized rats by integrating nasal inflammation, Th1/Th2-associated signaling, gut microbial composition, and short-chain fatty acids. The findings support a microbiota–immune connection, while the antibiotic-perturbation design offers a useful framework for testing whether intestinal changes contribute to treatment response.

• L. acidophilus, UDCA, and Immune Control in UC

  2026-08-17

  Deng et al. identify ursodeoxycholic acid (UDCA) as a microbiota-associated effector that helps explain how Lactobacillus acidophilus improves experimental ulcerative colitis. Their combined antibiotic-depletion, metabolomics, animal, and cell-based design links UDCA with enhanced Treg differentiation, reduced M1 macrophage polarization, and regulation of the RapGap/PI3K-AKT/NF-κB axis.

8048 records 7/537 page Previous Next First page 上5页 678910 下5页 Last page